



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, February 6th, 2025
1:05 PM - 4:45 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells; Jennifer Bowen; Michael Yu, DC; Kyle Hamilton

Audience: Patrick Boland*, Bristol Myers Squibb; Lynda Finch*, Biogen; Bill McDougall, Biogen; Jill Carroll, BMS; Shauna Williams, Biogen; Matt Respicio, EOCCO/Moda; Gary Parenteau, Dexcom; Greg Kitchens, Artia Solutions; Melissa Snider, Gilead; Maggie Bennington-Davis, Health Share; Bryan Armstrong, CareOregon; Chris Ferrin, IHN; Shauna Wick; Nirmal Ghuman, J&J; Lisa Pulver, J&J; Pam Storey, PTC Therapeutics; China Izatt, Syndax; Divine Marcelo, Amgen; Elva Van Devender, Umpqua Health; Mark Kantor, AllCare Health; Paul Thompson, Alkermes; Brett Freund; Michele Sabados, Alkermes; Amy Breen, Teva; Jay Patel; Daria Meleshkina, Moda/EOCCO; Erin Nowak, AbbVie; Tammi Ocumpaugh; Lori McDermott, Viking HCS

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Election of Chair and Vice Chair
 - Dr. Ramirez volunteered to serve as Chair and Dr. Stevens as Vice-Chair**
 - ACTION: Motion to approve, 2nd, all in favor**
- D. Approval of Agenda and December 2024 Minutes presented by Roger Citron, RPh
 - ACTION: Motion to approve, 2nd, all in favor**
- E. Department Updates:
 - a. HERC Update provided by Sarah Servid, PharmD



- b. Legislative Update provided by Trevor Douglass, DC
- c. MHCAG Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

- A. **P&T Evidence Methods**
- B. **P&T Policies and Procedures**
- C. **SGLT-2 Inhibitor Literature Scan**
Recommendations:
 - No changes to the PDL are recommended based on review of the evidence
 - Update PA criteria to include evidence of benefit for empagliflozin in patients with CKD without diabetes
 - Evaluate costs in executive session
- D. **Orphan Drug Policy Updates**
Recommendation:
 - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Kebilidi (eladocogene exuparvovec-tneq) based on FDA-approved label
- E. **Oncology Prior Authorization (PA) Updates**
Recommendation:
 - Add: Unloxcyt™ (cosibelimab-ipdl); Ensacove™ (ensartinib); Opdivo™ Qvantig (nivolumab and hyaluronidase-nvhy); Aucatzyl™ (obecabtagene autoleucel); Revuforj™ (revumenib); Ziihera® (zanidatamab-hrii); and Bizengri® (zenocutuzumabzbc) to Table 1 in the Oncology Agents PA criteria**ACTION: Motion to approve, 2nd, all in favor**

III. DUR ACTIVITIES

- A. **Quarterly Utilization Report:** Roger Citron, RPh
- B. **ProDUR Report:** Lan Starkweather, PharmD
- C. **RetroDUR Report:** Dave Engen, PharmD
- D. **Oregon State Drug Review:** Kathy Sentena, PharmD
 1. **Lifestyle Modifications for Obesity: Recommendations and Benefits**
 2. **Applying the Science of Pharmacogenomics to Clinical Practice**
 3. **Respiratory Syncytial Virus – Guidance for the Upcoming Season**

IV. NEW BUSINESS

- A. **Laxatives, Antidiarrheals, and Rifamycins Class Updates focused on treatment of Irritable Bowel Syndrome, Hepatic Encephalopathy, and Traveler's Diarrhea:** Deanna Moretz, PharmD
Recommendation:
 - Make rifaximin non-preferred on the PDL and update Rifaximin & Rifamycin PA criteria with the expanded indication for rifaximin in the management of IBS-D



- Auto-PA rifamixin when prescribed with lactulose
- Add alosetron, attapulgate, difenoxin/atropine, and telotristat etiprate to Antidiarrheals class and designate as non-preferred
- No other changes to the PDL are recommended based on clinical evidence
- Add pathway to coverage for adults with IBS-C or IBS-D to the Drugs for Constipation PA criteria
- Evaluate costs in executive session

ACTION: The Committee recommended looking back 60 days for the lactulose claim

Motion to approve, 2nd, all in favor

B. Parkinson's Disease Drugs Class Update: Dave Engen, PharmD

Recommendations:

- Update Parkinson's Disease Drugs PA criteria to support medically appropriate use of foscarnidopa/foslevodopa in advanced Parkinson's disease
- esignate Kisunla™ (donanemab) as non-preferred on the PDL
- No PDL changes are recommended based on clinical evidence
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. Cobenfy™ (xanomeline/trospium chloride) New Drug Evaluation (NDE): Sarah Servid, PharmD

Recommendations:

- Designate xanomeline/trospium as voluntary non-preferred
- Implement proposed PA criteria

Public Comment: Patrick Boland, Bristol Myers Squibb

ACTION: The Committee recommended amending question #3 to require attestation that benefits outweigh risks if intended to be used concomitantly with another antipsychotic

Motion to approve, 2nd, 6 in favor and 2 opposed

D. Skyclaris® (omaveloxolone) Prior Authorization Update: Deanna Moretz, PharmD

Recommendations:

- Amend clinical PA criteria to: require prescribing by a neurologist; add genetic confirmation of FDRA, and remove requirement for patients to be ambulatory

Public Comment: Lynda Finch, Biogen

ACTION: The Committee amended the proposal to require prescribing by a neurologist to include "or in consultation with"

Motion to approve, 2nd, all in favor

E. Vafseo® (vadadustat) New Drug Evaluation: Sara Fletcher, PharmD

Recommendations:

- Maintain vadadustat as non-preferred on the PDL
- Implement proposed Vadadustat PA criteria to ensure appropriate and safe use
- Retire Daprodustat PA criteria

ACTION: Motion to approve, 2nd, all in favor



F. Veozah® (fezolinetant) Prior Authorization Update: Deanna Moretz, PharmD

Recommendations:

- Revise PA criteria to stipulate duration of hormonal step therapy, add a recommendation for use of SSRI, SNRI, or gabapentin in addition to hormonal therapy, and add recent FDA guidance for liver function monitoring while taking fezolinetant

ACTION: Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Eddie Saito, PharmD; Jeanne Savage, MD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. SGLT-2 Inhibitor Literature Scan

Recommendation: Make canagliflozin non-preferred

ACTION: Motion to approve, 2nd, all in favor

B. Laxative, Antidiarrheal & Rifamycin Class Update

Recommendations: Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

C. Parkinson's Disease Drugs Class Update

Recommendations: Make foscarnidopa-foslevodopa (Vyalev™) vial non-preferred and make ropinirole HCL tablets preferred

ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN